Title: Pipeline Review on Lung Transplantation Therapeutic Industry, H1 2014
1Lung Transplantation - Pipeline Review, H1 2014
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
- Published January 2014
- Single User PDF US 2000
- Corporate User PDF US 6000
2 Lung Transplantation - Pipeline Review,
H1 2014
- Lung Transplantation - Pipeline Review, H1
2014'', provides an overview of the indications
therapeutic pipeline. This report provides
information on the therapeutic development for
Lung Transplantation, complete with latest
updates, and special features on late-stage and
discontinued projects. It also reviews key
players involved in the therapeutic development
for Lung Transplantation. Lung Transplantation-
Pipeline Review, Half Year is built using data
and information sourced from databases,
Company/University websites, SEC filings,
investor presentations and featured press
releases from company/university sites and
industry-specific third party sources, put
together by research team. - Scope
- A snapshot of the global therapeutic scenario for
Lung Transplantation. - A review of the Lung Transplantation products
under development by companies and
universities/research institutes based on
information derived from company and
industry-specific sources. - Coverage of products based on various stages of
development ranging from discovery till
registration stages. - A feature on pipeline projects on the basis of
monotherapy and combined therapeutics. - Inquiry Before Buying on this Report _at_
http//www.reportsnreports.com/contacts/InquiryBef
oreBuy.aspx?name274908.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3 Lung Transplantation - Pipeline Review,
H1 2014
- Coverage of the Lung Transplantation pipeline on
the basis of route of administration and molecule
type. - Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Reasons to buy
- Identify and understand important and diverse
types of therapeutics under development for Lung
Transplantation. - Identify emerging players with potentially strong
product portfolio and design effective
counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by
identifying players of the most promising
pipeline. - Devise corrective measures for pipeline projects
by understanding Lung Transplantation pipeline
depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing
strategies by identifying prospective partners
with the most attractive projects to enhance and
expand business potential and scope. - Modify the therapeutic portfolio by identifying
discontinued projects and understanding the
factors that drove them from pipeline. - Inquire for Discount _at_ http//www.reportsnreports.
com/contacts/Discount.aspx?name274908 -
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4 Lung Transplantation - Pipeline Review,
H1 2014
- List of Tables
- Number of Products under Development for Lung
Transplantation, H1 2014 7 - Number of Products under Development for Lung
Transplantation - Comparative Analysis, H1 2014 8 - Number of Products under Development by
Companies, H1 2014 9 - Comparative Analysis by Late Stage Development,
H1 2014 10 - Comparative Analysis by Early Stage Development,
H1 2014 11 - Lung Transplantation - Pipeline by Quark
Pharmaceuticals, Inc., H1 2014 12 - Lung Transplantation - Pipeline by Vectura Group
plc, H1 2014 13 - Lung Transplantation - Pipeline by Proteo, Inc.,
H1 2014 14 - Lung Transplantation - Pipeline by APT
Pharmaceuticals, Inc. (Inactive), H1 2014 15 - Lung Transplantation - Pipeline by Neopharm Ltd.,
H1 2014 16 - Assessment by Monotherapy Products, H1 2014 17
- Number of Products by Stage and Target, H1 2014
19 - Number of Products by Stage and Mechanism of
Action, H1 2014 21 - Number of Products by Stage and Route of
Administration, H1 2014 23 - Number of Products by Stage and Molecule Type, H1
2014 25
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5 Lung Transplantation - Pipeline Review,
H1 2014
- Number of Products by Stage and Therapeutic
Class, H1 2014 27 - Lung Transplantation Therapeutics - Recent
Pipeline Updates, H1 2014 36 - List of Figures
- Number of Products under Development for Lung
Transplantation, H1 2014 7 - Number of Products under Development for Lung
Transplantation - Comparative Analysis, H1 2014 8 - Number of Products under Development by
Companies, H1 2014 9 - Assessment by Monotherapy Products, H1 2014 17
- Number of Products by Top 10 Target, H1 2014 18
- Number of Products by Stage and Top 10 Target, H1
2014 19 - Number of Products by Top 10 Mechanism of Action,
H1 2014 20 - Number of Products by Stage and Top 10 Mechanism
of Action, H1 2014 21 - Number of Products by Top 10 Route of
Administration, H1 2014 22 - Number of Products by Stage and Top 10 Route of
Administration, H1 2014 23 - Number of Products by Top 10 Molecule Type, H1
2014 24
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
6 Lung Transplantation - Pipeline Review, H1
2014
- Number of Products by Top 10 Route of
Administration, H1 2014 23 - Number of Products by Stage and Top 10 Route of
Administration, H1 2014 24 - Number of Products by Top 10 Molecule Type, H1
2014 25 - Number of Products by Stage and Top 10 Molecule
Type, H1 2014 26 - Number of Products by Top 10 Therapeutic Class,
H1 2014 27 - Number of Products by Stage and Top 10
Therapeutic Class, H1 2014 28 - Complete report of 44 Pages is available _at_
http//www.reportsnreports.com/reports/274908-lung
-transplantation-pipeline-review-h1-2014.html
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.